Document:

<PAGE>

                                                                   Exhibit 10.19

                                 AMENDMENT NO. 3

                                       TO

              THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS ***

                                       AND

                          TRUBION PHARMACEUTICALS, INC.

Re:

Schedule 2 - Services

Updated Stages

     Stage 11 ***

Schedule 2

New Stages

     Add Stage 19 ***

     Add Stage 20 ***

     Add Stage 21 ***

Schedule 3

     Price and Payment

<PAGE>

THIS AMENDMENT is made the 7th day of February, 2005

BETWEEN

1.   LONZA BIOLOGICS ***, the registered office of which is at *** ("LB") and

2.   TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
     98121, USA (herein after referred to as the "Customer").

WHEREAS

A.   Customer and LB entered into a development and manufacturing services
     agreement dated 08 January 2004 ("the Agreement"), under which LB is
     required to perform Services relating to the Cell Line and the Product, as
     further described in the Agreement, and

B.   Customer would like LB to perform additional services under the Agreement,
     and

C.   LB is prepared to perform the additional services, and the parties wish to
     amend the Agreement accordingly.

NOW THEREFORE it is agreed as follows:

1. Schedule 2 of the Agreement shall be amended to revise Stage 11 (Reference
Standard Characterisation), as follows:

                                   SCHEDULE 2

Stage 11 of Schedule 2 shall now read in its entirety as follows:

STAGE 11 ***

     11.1 OBJECTIVES

          ***

     11.2 ACTIVITIES

          ***

     11.3 DELIVERABLES

          11.3.1 A report of activities carried out under this Stage 11 as
detailed in activity 11.2.4

<PAGE>

     11.4 TIMESCALE

     This Stage will commence as soon as Product is available from Stage 6 and
will be complete on issue of the final report of activities (activity 11.2.6)
and it is estimated that this shall be issued *** from the issue of protocol.

                                       -2-

<PAGE>

     2. Schedule 2 of the Agreement shall be amended to include the following
additional stages, Stage 19 (Stability Study (*** Pilot Material)), Stage 20
(Product Characterisation *** Pilot and *** cGMP Material) and Stage 21
(Shipping Trial):

STAGE 19 ***

     19.1 OBJECTIVES

     ***

     19.2 ACTIVITIES

     ***

     19.3 DELIVERABLES

          19.3.1 A summary report of activities to the Customer.

     19.4 TIMESCALE

     This Stage may commence as soon as Product is available and will be
complete upon issue of the summary report of activities.

     It is estimated that the summary report will be available within *** from
commencement.

STAGE 20 ***

     20.1 OBJECTIVES

          ***

     20.2 ACTIVITIES

          ***

     20.3 DELIVERABLES

          20.3.1 Report for the *** study.

          20.3.2 Data summaries of *** study.

          20.3.3 Report for the *** study.

          20.3.4 Audited data table summaries of ***from the *** study.

                                       -3-

<PAGE>

     20.4 TIMESCALE

     This Stage may commence as soon as Product is available and will be
complete upon issue of the final reports of activities.

     It is estimated that the audited data table summaries will be available
within *** from commencement.

     It is estimated that both final reports will be issued *** from
commencement.

                                       -4-

<PAGE>

STAGE 21 ***

     21.1 OBJECTIVES

          ***

     21.2 ACTIVITIES

          ***

     21.3 DELIVERABLES

          21.3.1 A non-cGMP report of activities, analysis and results of the
study.

     21.4 TIMESCALE

     This Stage may commence upon signature of this Amendment 3 and will be
complete upon issue of the (non-cGMP) report of activities.

     It is estimated that the (non-cGMP) report will be available within ***
month from commencement.

                                       -5-

<PAGE>

     3. Schedule 3 of the Agreement shall be amended by the addition of the
following provisions in respect of the additional Stages contained in this
Amendment No. 3;

                                   SCHEDULE 3

                           Price and Terms of Payment

1. Price

     In consideration for LB carrying out the updated Services described in
Stage 11 and the new Services as described in Stage 19, Stage 20 and Stage 21 as
detailed in Schedule 2 the Customer shall pay LB as follows:

     ***

2. Payment

     Payment by the Customer of the Price for each Stage -shall be made against
LB's invoices as follows:

2.1  For Stage 11

     100% upon completion of Stage 11.

2.2  For Stage 19

     100% upon completion of Stage 19.

2.2  For Stage 20

     100% upon completion of Stage 20.

2.2  For Stage 21

     100% upon completion of Stage 21.

3. Any capitalized term used but not defined in this Amendment No. 3 shall have
the meaning given in the Agreement.

4. Save as herein provided all other terms and conditions of the Agreement shall
remain in full force and effect.

     IN WITNESS WHEREOF the parties have caused this Amendment No. 3 to be
executed by their duly authorised representatives thereunto as of the day and
year first above written.

Signed for and on behalf of
LONZA BIOLOGICS ***                     ***
                                        ----------------------------------------

                                       -6-

<PAGE>

                                        ***                                Title
                                        ----------------------------------------

Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC.           /s/ Kendall Mohler
                                        ----------------------------------------
                                        Senior Vice President, Research &
                                        Development

                                       -7-<PAGE>

                                                                   Exhibit 10.20

                                                                           Lonza

                                 AMENDMENT NO. 4

                                       TO

              THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS ***

                                       AND

                          TRUBION PHARMACEUTICALS, INC.

Re:

Schedule 1

Schedule 2

     Stage 22 ***.

Schedule 3

     Price and Payment

<PAGE>

                                                                           Lonza

THIS AMENDMENT is made the 4th day of January, 2005

BETWEEN

1. LONZA BIOLOGICS ***, the registered office of which is at *** ("LB") and

2. TRUBION PHARMACEUTICALS, INC., 2401 4th Avenue, Suite 1050, Seattle, WA
98121, USA. ("Customer")

WHEREAS

A.   Customer and LB entered into an agreement dated 08 January 2004 as amended
     ("The Agreement"), under which LB is required to perform Services relating
     to the Cell line and Product described, and

B.   Customer would like LB to carry out additional activities under the
     Agreement, and

C.   LB is prepared to perform the additional activities.

NOW THEREFORE it is agreed hereby by the parties to amend the Agreement and
perform additional services as follows:

<PAGE>

                                                                           Lonza

1. Schedule 2 of the Agreement shall be amended to include the following
additional stage:

                                   SCHEDULE 2

STAGE 22 ***

     22.1 OBJECTIVE

          ***

     22.2 ACTIVITIES

          ***

     22.3 TIMESCALE

     This Stage commenced ***. This Stage will be complete on issue of all the
Protocols and Reports mentioned above in section 22.2.1.

                                       -2-

<PAGE>

2. Schedule 3 of the Agreement shall be amended by the addition of the following
provisions in respect of the additional Stages contained in this Amendment no.
4:

                                   SCHEDULE 3

                           Price and Terms of Payment

1.   Price

     In consideration for LB carrying out the Services as detailed in Schedule 2
the Customer shall pay LB as follows:

     ***

2.   Payment

     Payment by the Customer of the Price for each Stage shall be made against
LB's invoices as follows:

     2.1  For Stage 22

          *** upon commencement of Stage 22.

          *** upon completion of Stage 22.

     Save as herein provided all other terms and conditions of the Agreement
shall remain in full force and effect.

     IN WITNESS WHEREOF the parties have caused this Amendment No. 4 to be
executed by their representatives thereunto duly authorised as of the day and
year first written.

Signed for and on behalf of
LONZA BIOLOGICS ***                     ***
                                        ----------------------------------------
                                        ***                                Title
                                        ----------------------------------------

Signed for and on behalf of
TRUBION PHARMACEUTICALS INC.            /s/ Peter A. Thompson
                                        ----------------------------------------
                                        President & CEO                    Title

                                       -3-<PAGE>

                                                                   Exhibit 10.21

                                 AMENDMENT NO. 5

                                       TO

                        THE DEVELOPMENT AND MANUFACTURING
                               SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS ***

                                       AND

                          TRUBION PHARMACEUTICALS, INC.

<PAGE>

THIS AMENDMENT No. 5 ("Fifth Amendment") is made the 18th day of February, 2005

BETWEEN

LONZA BIOLOGICS *** of *** (hereinafter referred to as "LB"), and

TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
98121, USA (hereinafter referred to as the "Customer")

WHEREAS

A.   LB and the Customer entered into a development and manufacturing services
     agreement ("the Agreement") dated 08 January 2004, pursuant to which LB
     agreed to provide Services to the Customer, and,

B.   The Customer now wishes LB to perform additional services under the
     Agreement, and,

C.   LB is willing to perform such additional services on the terms set out in
     the Agreement, and

D.   The parties wish to amend the Agreement in accordance with Clause 13.5
     thereto.

NOW THEREFORE IT IS HEREBY AGREED as follows:

1.   Two new stages, Stages 23 and 24, shall be added to Schedule 2 of the
     Agreement to read as follows:

STAGE 23 ***

     23.1 OBJECTIVES

          ***

     23.2 ACTIVITIES

          ***

     23.3 DELIVERABLES

          23.3.1 Copies of all Process specific documentation prepared in
activity 23.2.1 which has not already been supplied to the Customer

     23.4 TIMESCALE

     Stage 23 will be scheduled in to the Services in such a way that it is not
rate limiting and shall be complete when LB and the Customer have approved the
documentation and when a copy of the approved final bulk Product specification
has been sent to the Customer.

<PAGE>

     It is estimated that Stage 23 will be complete approximately *** from the
commencement of Stage 23.

STAGE 24 ***

     24.1 OBJECTIVES

     ***

     24.2 ACTIVITIES

     ***

     24.3 DELIVERABLES

          24.3.1 A Certificate of Analysis for the Batch of bulk Product
manufactured.

          24.3.2 If requested by Customer, a copy of the completed manufacturing
batch record.

          24.3.3 The manufactured Product, including samples and in-Process
samples to be supplied to Customer as agreed by the parties.

     NOTE: ***.

     24.4 TIMESCALE

          Stage 24 shall be complete upon issue to the Customer of the
Certificate of Analysis for the Batch of Product manufactured.

          It is estimated that the Certificate of Analysis will be issued
approximately *** from commencement of this Stage (estimated out of freeze ***).
If the Customer requests in writing, the Product can be shipped in quarantine
prior to release. It is estimated that this shipment could occur *** from
commencement of this Stage.

                                      -2-

<PAGE>

2. Schedule 3 to the Agreement shall be amended to include provision for payment
for the above mentioned additional Service, as set out below hereto. Invoices
for these additional Services shall be issued, and Customer payments shall be
made, in U.S. dollars:

     1. Price

     ***

     2. Payment

     For Stage 23

          *** upon commencement of Stage 23.

          *** upon completion of Stage 23.

     For Stage 24

          *** upon commencement of the batch

          *** upon issue of the Certificate of analysis for the Batch.

3. *** as Permitted Subcontractor. The Agreement is amended to provide that LB
shall cause ***, in its capacity as a permitted subcontractor to LB under the
Agreement, to perform the Services described in Stages 23 and 24 of the
Agreement, to the extent necessary or useful to LB in LB's performance of the
services under the Agreement, and to provide all other assistance necessary or
useful to LB in LB's performance of the Services, including all assistance
required in order to implement the Process at ***, and the Customer consents to
the foregoing. In connection with the foregoing, LB shall cause *** to comply
with the terms of the Agreement, and such subcontracting shall not relieve LB of
and LB shall remain primarily liable for the performance of LB's obligations
under the Agreement.

4. Authority; Conflicts. Each party represents and warrants that (a) it has the
corporate power and authority and the legal right to enter into this Fifth
Amendment and to perform its obligations hereunder and under the Agreement (as
amended by this Fifth Amendment), and (b) it is not a party to any agreement
that does not permit or that prohibits it from fulfilling its obligations under
this Fifth Amendment or under the Agreement (as amended by this Fifth
Amendment), and each party covenants that it shall not enter into any agreement
that would not permit or would prohibit it from performing its obligations
hereunder and under the Agreement, including without limitation the Services
described in this Fifth Amendment. Furthermore, LB represents and warrants that,
to the best of its knowledge, after reasonable inquiry (a) *** has the legal
right to perform the Services described in Stages 23 and 24 of the Agreement,
and (b) *** is not a party to any agreement that does not permit or that
prohibits it from performing the Services described in Stages 23 and 24 of the
Agreement.

5. Miscellaneous.

     5.1 Any capitalised term used but not defined in this Fifth Amendment shall
have the meaning given in the Agreement. In the event of a conflict between the
terms of this Fifth Amendment and the Agreement, the terms of this Fifth
Amendment shall control.

                                      -3-

<PAGE>

     5.2 This Fifth Amendment may be executed in counterparts, each of which
shall be deemed an original and all of which, taken together, shall constitute
one and the same agreement. This Fifth Amendment shall be effective upon full
execution by facsimile or original.

     Save as herein provided all other terms and conditions of the Agreement
shall remain in full force and effect.

     AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.

Signed for and on behalf of
LONZA BIOLOGICS ***                     ***
                                        ----------------------------------------

                                        ***
                                        ----------------------------------------
                                                                           Title

Signed for and on behalf of
TRUBION PHARMACEUTICALS INC.            /s/ Peter A. Thompson
                                        ----------------------------------------
                                        President & CEO                    Title

                                      -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]